CORPORATE OVERVIEW

Two technologies, one objective. To covert cancer and other degenerative diseases into non-lethal manageable conditions

Novogen Ltd is a public Australian drug development company whose shares trade on both the Australian Securities Exchange ('NRT') and NASDAQ ("NVGN"). The Novogen group includes a New Haven CT-based joint venture company, CanTx Inc., with Yale University

Novogen's unique position

Novogen differentiates itself in the marketspace from all other stem cell and cancer therapy biotech companies by developing a product that will target the stem cell and the somatic cell in the one drug.

Novogen has two main drug technology platforms: Superbenzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been created to kill the full range of cells within a tumor. The ATM compounds target the microfilament component of the cancer cell and when used in conjunction with standard anti-microtubular drugs, result in comprehensive and fatal destruction of the cancer cell's cytoskeleton.

ONCOLOGY PROGRAM

Cantrixil

* First in man studies expected to commence Q3 2015 in late stage ovarian cancer patients and malignant ascites patients
* Final test in an animal model developed in conjunction with CanTx Inc. successful in eradicating tumor development in the great majority of mice
* Cantrixil is being developed as a first-line, second-line and salvage therapy for ovarian cancer and the treatment of late stage conditions, malignant ascites and malignant pleural effusion

Trx-7

* Currently in the development stage for prostate cancer

Trilexium

ATM

Other Programs

Novogen Vision

"Our vision is for the SBP and ATM drug technologies to provide a combination chemotherapy regimen that will become the standard first-line therapy for most forms of cancer. Used together they will provide comprehensive killing of the full hierarchy of tumor cells, thereby preventing or stalling disease relapse and the development of refractory cancer"

Partnerships

Novogen has a global presence with offices in Australia and the US. Novogen partners with many universities, hospitals and research centers around the globe giving it the ability to bring clinical trials globally and ensure the best option is considered.

Genea Biocells

Novogen in partnership with Genea will test molecules in laboratory models across a range of degenerative diseases including fascioscapulahumeral dystrophy, Alzheimer's, Sanfillipo syndrome and infantile neuraxonal dystrophy. The collaboration is on the basis of pooling resources and each company retaining its own IP and commercial opportunities

Yale University

On the 7th November, 2013, Novogen formed a joint venture CanTx Inc. with Yale University. The joint venture is based in New Haven Connecticut and is owned 85% by Novogen. CanTx R&D will be centred at the laboratories of Prof. Gil Mor, Yale Medical School.

CODA

Children's Oncology Kids Alliance

In May, 2014, Novogen became the founding investor in a new partnership called CODA, formed to facilitate the development of treatments for childhood cancers.

"Super-benzopyrans are the first drug class we have seen with the ability to selectively modulate misbehaving stem cells"

- Dr Uli Schmidt, General Manager of Genea Biocells

"An obvious strategy is to be more successful in treating primary disease, so that we stop the development of recurrent disease. We need to be able to kill the ovarian cancer stem cells before they have the chance to produce a second generation of highly chemo resistance daughter cells". - Professor Gil Mor, Yale

The Holy Grail of childhood cancer therapy is a medicine that is effective against a tumor such as neuroblastoma, but doesn't leave the sort of damage that the child then has to deal with for the rest of his or her life.—Dr Graham Kelly Novogen CEO

Therapeutic Field	Program	Discovery	Preclinical	Phase 1	Phase 2	Phase 3	Expected Trial commencement
Oncology	Cantrixil						Q3 2015
Oncology	Trx-7						Q3 2015
Oncology	Trilexium						Q4 2015
Oncology	ATM						Q4 2015
Degenerative program	Stem Cell regeneration						
Degenerative program	Neurodegenerative Diseases						
Degenerative program	Muscular Dystrophy						
Degenerative program	Lysosomal Storage Disorder						
Autoimmune Disease	Autoimmune Disease						
Regenerative Disease	Regenerative Diseases						